PPD Appoints Product Development VP

Michael Gold, M.D., has been appointed to serve as vice president of global product development, joining PPD’s neuroscience team.
 
Dr. Gold joined the company after serving in leadership roles in major pharmaceutical and biotech companies, as well as academia. Most recently, he spent two years at UCB Bioscience as vice president of global therapeutic area, central nervous system. Previously, he worked for nearly three years at Allon Therapeutics as vice president and chief medical officer. From 2005 to 2011, Dr. Gold was with GSK, where he served as medicines development leader for Alzheimer’s disease and vice president of neurosciences, medicines development center.
 
“Mike adds impressive depth to PPD’s neuroscience medical team, which offers expertise across a range of disorders,” said Rob Dow, senior vice president, global product development for PPD. “Mike’s broad experience in the development of new medicines spans a variety of neurologic conditions, and his expertise in the field of neurodegenerative diseases, including Alzheimer’s and other forms of dementia, is of great value to our clients, as we work together to advance treatment options for these debilitating diseases.”